Fetroja
(Cefiderocol)ApprovedSmall molecule
ShionogiFetroja is one of 77 small molecule programs targeting Gram-Negative Bacterial Infections. It is currently in Approved.
5
Indications
19
Total Trials
4
Active Trials
76
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Fetroja
ShionogiApproved
Ibsrela
AArdelyx
Phase 3
Biaxin
AbbViePhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Myambutol
VVA Greater Los Angeles Healthcare System
Phase 2
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pediatric2 trials
Severe Infection1 trial
Midazolam1 trial
13 more indications
Ampicillin1 trial
Bacterial Infections1 trial
Renal Replacement Therapy1 trial
Gram-Negative Bacterial Infections1 trial
Infants1 trial
Pneumonia1 trial
Urinary Tract Infection1 trial
Adult1 trial
Liver1 trial
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase-producing Enterobacterales Undergoing Liver Transplantation: a Stepped Wedge Cluster Randomization Trial
Not yet recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT07759453·168 enrolled
Regulatory
FDA Approval Timeline[4]
Nov 14, 2019
FETROJA
NDA NDA209445
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefiderocol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]